Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 971 to 980 of 1106 total matches.
Tinidazole (Tindamax) - A New Anti-Protozoal Drug
The Medical Letter on Drugs and Therapeutics • Aug 30, 2004 (Issue 1190)
— Approval of tinidazole was based on pooled data from studies conducted in the 1970s and 1980s. In a small ...
Tinidazole (Tindamax - Presutti Labs), an oral antiprotozoal drug similar to metronidazole (Flagyl, and others), has been approved by the FDA for treatment of trichomoniasis in adults and for treatment of giardiasis, intestinal amebiasis and amebic liver abcess in adults and children more than 3 years old. Tinidazole has been widely used outside of the US for decades under the trade name Fasigyn (Pfizer).
Duloxetine (Cymbalta): A New SNRI for Depression
The Medical Letter on Drugs and Therapeutics • Oct 11, 2004 (Issue 1193)
on the most recent data (August
31, 2004) from retail pharmacies nationwide available from NDCHealth ...
Duloxetine hydrochloride (Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI), has been approved by the FDA for treatment of major depressive disorder in adults, and more recently for diabetic peripheral neuropathy as well. The Medical Letter will review its role in diabetic neuropathy in a future issue.
Alprazolam (Xanax, and others) Revisited
The Medical Letter on Drugs and Therapeutics • Jan 17, 2005 (Issue 1200)
of 20
mg/day (prices based on the most recent data
[November 30, 2004] from retail pharmacies ...
Alprazolam, a short-acting benzodiazepine, is one of the most widely prescribed drugs in the US. It is approved by the FDA for treatment of anxiety and panic disorder. An extended-release formulation, Xanax XR, which can be taken once a day, recently became available for panic disorder.
Palladone for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005 (Issue 1204)
recent data ( January 31, 2005 ) from retail pharmacies nationwide available from
NDCHealth ...
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride (Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms (Dilaudid, and others).
Micafungin (Mycamine) for Fungal Infections
The Medical Letter on Drugs and Therapeutics • Jun 20, 2005 (Issue 1211)
’ treatment of a 70-kg patient at the highest dosage, according to the most recent data (April 30, 2005 ...
Micafungin sodium (Mycamine - Astellas), the second echinocandin antifungal to become available in the US, has been approved by the FDA for intravenous treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT).
Sildenafil (Revatio) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
. Based on most recent data (June 30, 2005) from retail pharmacies nationwide available from NDCHealth ...
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio.
Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006 (Issue 1226)
and meningococcal vaccines), but data on the efficacy
and safety of doing so are limited.
CONCLUSION — The 2 new ...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine...
Transdermal Methylphenidates (Daytrana) for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006 (Issue 1237)
. Cost for 30 days' treatment, based on most recent data (April 30, 2006) from retail pharmacies ...
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June.
Insulin Detemir (Levemir), a New Long-Acting Insulin
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006 (Issue 1238)
, syringe or prefilled pen (100 units/mL) based on most recent data (May 31, 2006) from retail
pharmacies ...
Insulin detemir (Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus), the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting...
Nabilone (Cesamet) for Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
with the lowest dosage according to the most
recent data (October 31, 2006) from retail pharmacies nationwide ...
Nabilone, an oral synthetic cannabinoid similar to delta-9-tetrahydrocannabinol (THC), the active ingredient in marijuana, has recently been reintroduced to the US market (Cesamet - Valeant) after a 17-year absence. The previous manufacturer discontinued marketing of the drug for commercial reasons. Nabilone is classified as a Schedule II controlled substance.